By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment Bank Leerink Swann this week upgraded its rating on Bio-Rad Laboratories' stock from "market perform" to "outperform," citing a favorable trend for the firm's diagnostics business over the immediate term. The bank also placed a 12-month valuation range of between $107 and $114 on the stock. Bio-Rad closed Wednesday, the day the note was issued, at $98.75.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.